[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 835
Citations 0
Comment & Response
April 2015

What Ecologic Analyses Cannot Tell Us About Medical Marijuana Legalization and Opioid Pain Medication Mortality

Author Affiliations
  • 1Center for Innovation to Implementation, VA Palo Alto Health Care System, Menlo Park, California
  • 2Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
  • 3Department of Orthopedic Surgery, Stanford University School of Medicine, Stanford, California
JAMA Intern Med. 2015;175(4):655-656. doi:10.1001/jamainternmed.2014.8006

To the Editor Bachhuber et al1 found that states with legalized medical marijuana and those that had longer periods of legalized medical marijuana had lower adjusted opioid analgesic mortality rates than those that did not. Although they acknowledged that mechanisms underlying these relationships are speculative, the one receiving the most attention was that medical marijuana may reduce patients’ reliance on opioid pain medications, thereby reducing their mortality risk. The authors noted that one limitation of their analyses was that they were “ecologic” (ie, linking state-level variables), so they “cannot adjust for characteristics of individuals within the states….”1(p1671) We would suggest that the primary drawback of the ecologic analyses is that they provide no information whether individual pain patients who use marijuana have a lower or higher opioid analgesic mortality risk.

First Page Preview View Large
First page PDF preview
First page PDF preview
×